Lorazepam |
0.5–2.0 |
Reliably absorbed when injected into the muscle; short half-life; no active metabolites; can potentially treat alcohol withdrawal; relatively inexpensive |
No antipsychotic effect; potential for respiratory depression; risk for behavioral disinhibition (paradoxical reaction); development of tolerance |
Haloperidol |
0.5–7.5 |
Antipsychotic effect over time; relatively inexpensive |
Akathisia; dystonia; will not treat underlying alcohol withdrawal |
Ziprasidone |
10–20 |
Antipsychotic effect over time; favorable extrapyramidal symptom profile compared to first-generation antipsychotics |
Explicit warning in product labeling regarding prolongation of the QTc interval; will not treat underlying alcohol withdrawal; relatively more costly but availability of generic product will impact on price |
Olanzapine |
10 (5 or 7.5 when clinically warranted) |
Antipsychotic effect over time; favorable extrapyramidal symptom profile compared to first-generation antipsychotics |
Concomitant administration of intramuscular olanzapine and parenteral benzodiazepine is not recommended due to the potential for excessive sedation and cardiorespiratory depression; weight gain over time; will not treat underlying alcohol withdrawal; relatively more costly but availability of generic product will impact on price |
Aripiprazole |
9.75 |
Antipsychotic effect over time; favorable extrapyramidal symptom profile compared to first-generation antipsychotics |
No dosage adjustment of aripiprazole is required when administered concomitantly with lorazepam but the intensity of sedation was greater with the combination as compared to that observed with aripiprazole alone and the orthostatic hypotension observed was greater with the combination as compared to that observed with lorazepam alone; will not treat underlying alcohol withdrawal; relatively more costly and remains under patent exclusivity at present |